Cool heads in a crisis?
Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics
First there was Ebola and now there is Zika; two official World Health Organization (WHO) Public Health Emergencies of International Concern (PHEIC) within as many years. Whenever global health crises such as these emerge, the pharmaceutical industry comes under intense scrutiny for not having an immediate solution available. Part of the problem is that prevention is not always financially viable; the substantial R&D costs of developing vaccines or treatments for all known and potential threats that may or may not one day develop into global pandemics is not a feasible burden for the industry to carry alone.
Biosimilars: Bringing patients into the conversation
Published in eyeforpharma January 2017 by Mariel Metcalfe
In a recent white paper, we explored the impact that biosimilars are having and likely to have on the rising cost of RA treatment. We looked at physician attitudes to biosimilars and the challenges manufacturers face in gaining widespread acceptance.
Access and elimination: the future of DAAs in hepatitis C
Published in Pharmaphorum January 2017
The dramatic improvements in safety, efficacy, tolerability and convenience from the first wave of direct-acting antivirals (DAAs) have made a substantial contribution to changing both the treatment paradigm and the long-term prognosis for hepatitis C.
The arrival of interferon-free, orally administered direct-acting antivirals (DAAs) in 2014 was a leap forward for the treatment of hepatitis C (HCV), a disease responsible for some 700,000 deaths globally each year.
Nutraceuticals in India: A Challenging Opportunity
Published in eyeforpharma December 2016 by Marc Yates
As growth begins to plateau in more established territories, attention is turning to emerging markets with a fast-expanding middle class. One of these is India. It cannot quite compete with China for sheer volume of potential consumers: China has a population of around 1.38 billion compared with 1.31 billion in India, although the Indian population is expected to catch up by 2022. On the other hand, a significantly larger proportion of the Chinese population lives in urban environments, where factors such as improved access to healthcare, higher disposable income and more exposure to diseases of affluence will create greater demand for nutraceuticals. Nonetheless, India offers considerable potential for growth from a modest base, currently estimated at 1-2% of global nutraceutical sales. To deliver fully on that promise, though, food and pharmaceutical companies need to address a number of regulatory, cultural, economic and structural challenges in the Indian market.
Nutraceuticals: Rich in potential
Published in eyeforpharma October 2016 by Marc Yates
A shift to preventative health will see nutraceuticals emerge as a growth area across mature and emerging markets.
The strong growth and globalization of the nutraceuticals sector may be down to the ingenuity of brand managers as much as food scientists, but it also reveals a lot about current trends in healthcare and the cultural, economic or demographic factors underlining them, across both mature and emerging markets. What is interesting about the nutraceuticals boom is that no-one has really agreed yet what these products are exactly, or at least where they sit in standardized legal and regulatory terms either at country level or worldwide.